Since shortly Gen-Plus is registered in the CIR–program of the French government, thus providing substantial re-imbursement opportunities for R&D costs of innovative development projects.

Our French customers are sure to welcome this financial aid. For us at Gen-Plus the CIR-program means an additional push in one of our fastest growing business areas as R&D costs are quite dominant in our projects.

By CIR we expect essential competitive advantages leading to a welcomed expansion of our activities in France.

Related Posts

  • Gen Plus @ European Drug Delivery Summit

    read more

  • In-vitro Permeation and Penetration Testing in Gen-Plus

    read more

  • Are you a GMP person?

    read more